Iron chelation therapy in thalassemia major: A systematic review with meta-analyses of 1520 patients included on randomized clinical trials

Aurelio Maggio, Aldo Filosa, Angela Vitrano, Giuseppina Aloj, Antonis Kattamis, Adriana Ceci, Suthat Fucharoen, Paolo Cianciulli, Robert W. Grady, Luciano Prossomariti, John B. Porter, Angela Iacono, Maria Domenica Cappellini, Fedele Bonifazi, Filippo Cassarà, Paul Harmatz, John Wood, Christian Gluud

Research output: Contribution to journalArticle

Abstract

The effectiveness of deferoxamine (DFO), deferiprone (DFP), or deferasirox (DFX) in thalassemia major was assessed. Outcomes were reported as means±SD, mean differences with 95% CI, or standardized mean differences. Statistical heterogeneity was tested using Χ 2 (Q) and I 2. Sources of bias and Grading of Recommendations Assessment, Development and Evaluation system (GRADE) were considered. Overall, 1520 patients were included. Only 7.4% of trials were free of bias. Overall measurements suggest low trial quality (GRADE). The meta-analysis suggests lower final liver iron concentrations during associated versus monotherapy treatment (p

Original languageEnglish
Pages (from-to)166-175
Number of pages10
JournalBlood cells, molecules & diseases
Volume47
Issue number3
DOIs
Publication statusPublished - Oct 15 2011

    Fingerprint

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Hematology
  • Cell Biology

Cite this

Maggio, A., Filosa, A., Vitrano, A., Aloj, G., Kattamis, A., Ceci, A., Fucharoen, S., Cianciulli, P., Grady, R. W., Prossomariti, L., Porter, J. B., Iacono, A., Cappellini, M. D., Bonifazi, F., Cassarà, F., Harmatz, P., Wood, J., & Gluud, C. (2011). Iron chelation therapy in thalassemia major: A systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood cells, molecules & diseases, 47(3), 166-175. https://doi.org/10.1016/j.bcmd.2011.07.002